An investor, who purchased NASDAQ:HZNP shares filed a lawsuit in the U.S. over alleged violations of Federal Securities Laws by Horizon Pharma Inc
Investors who purchased shares of Horizon Pharma Inc (NASDAQ:HZNP) have certain options and for certain investors are short and strict deadlines running. Deadline: May 9, 2016. NASDAQ:HZNP investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.
The plaintiff claims that between March 13, 2014 and February 26, 2016 Defendants made allegedly false and/or misleading statements and/or allegedly failed to disclose that Horizon’s Prescriptions Made Easy (“PME”) program was designed to artificially inflate the prices of minor differentiation standard retail drugs, that sales revenues from drugs sold through Horizon’s PME program were unsustainable at these inflated price levels, that Horizon’s use of its PME program left the Company subject to increased regulatory risks, that Horizon received a subpoena from the Office of the U.S. Attorney for the Southern District of New York in November 2015, and that as a result of the foregoing, Defendants’ statements about Horizon’s business, operations, and prospects were false and misleading and/or lacked a reasonable basis.
On February 29, 2016, Horizon Pharma Inc disclosed in its 2015 annual report that the Company received a subpoena in November 2015 from the Office of the U.S. Attorney for the Southern District of New York for documents and information related to the Company’s patient assistance programs, which include providing free medicines and copay coupons to help cover out-of-pocket drug costs, and other aspects of Horizon’s sales and marketing activities.
Those who purchased NASDAQ:HZNP shares have certain options and should contact the Shareholders Foundation.
Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North – Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com